Safety and efficacy of REP 2139 and pegylated interferon alfa-2α for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial (vol 2, pg 877, 2017)

被引：0
|
作者：
Bazinet, M.
Pantea, V
Cebotarescu, V
机构：
来源：
LANCET GASTROENTEROLOGY & HEPATOLOGY | 2018年 / 3卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：E1 / E1
页数：1
相关论文
共 40 条
  • [1] Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open-label, phase 2 trial
    Bazinet, Michel
    Pantea, Victor
    Cebotarescu, Valentin
    Cojuhari, Lilia
    Jimbei, Pavlina
    Albrecht, Jeffrey
    Schmid, Peter
    Le Gal, Frederic
    Gordien, Emmanuel
    Krawczyk, Adalbert
    Mijocevic, Hrvoje
    Karimzadeh, Hadi
    Roggendorf, Michael
    Vaillant, Andrew
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2017, 2 (12): : 877 - 889
  • [2] Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment of naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): a non-randomised, open label, phase 2 trial
    不详
    CHIMICA OGGI-CHEMISTRY TODAY, 2018, 36 (02) : 54 - 55
  • [3] Initial Follow Up Results from the REP 301 Trial: Safety and Efficacy of REP 2139-Ca and Pegylated Interferon Alpha-2a in Caucasian Patients with Chronic HBV / HDV Co-infection
    Bazinet, Michel
    Pantea, Victor
    Cebotarescu, Valentin
    Cojuhari, Lilia
    Jimbei, Paulina
    Albrecht, Jeffrey
    Schmid, Peter
    Krawczyk, Adalbert
    Karimzadeh, Hadi
    Roggendorf, Michael
    Valliant, Andrew
    HEPATOLOGY, 2016, 64 : 912A - 912A
  • [4] Establishment of persistent functional remission of HBV and HDV infection following REP 2139 and pegylated interferon alpha 2a therapy in patients with chronic HBV/HDV co-infection: 18 month follow-up results from the REP 301-LTF study
    Bazinet, M.
    Pantea, V.
    Cebotarescu, V.
    Cojuhari, L.
    Jimbei, P.
    Vaillant, A.
    JOURNAL OF HEPATOLOGY, 2018, 68 : S509 - S509
  • [5] One year follow-up and HBV RNA / HBcrAg analysis in the REP 301 Trial: REP 2139 and pegylated interferon alpha-2a in Caucasian patients with chronic HBV / HDV co-infection
    Bazinet, M.
    Pantea, V.
    Cebotarescu, V.
    Cojuhari, L.
    Jimbei, P.
    Krawczyk, A.
    Vaillant, A.
    JOURNAL OF HEPATOLOGY, 2017, 66 (01) : S96 - S97
  • [6] ONGOING ANALYSIS OF FUNCTIONAL CONTROL / CURE OF HBV AND HDV INFECTION FOLLOWING REP 2139-CA AND PEGYLATED INTERFERON ALPHA-2a THERAPY IN PATIENTS WITH CHRONIC HBV / HDV CO-INFECTION: 3-YEAR FOLLOW-UP RESULTS FROM THE REP 301-LTF STUDY
    Bazinet, Michel
    Pantea, Victor
    Cebotarescu, Valentin
    Cojuhari, Lilia
    Jimbei, Pavlina
    Krawczyk, Adalbert
    Dittmer, Ulf
    Vaillant, Andrew
    HEPATOLOGY, 2019, 70 : 440A - 440A
  • [7] Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
    Kowdley, Kris V.
    Lawitz, Eric
    Crespo, Israel
    Hassanein, Tarek
    Davis, Mitchell N.
    DeMicco, Michael
    Bernstein, David E.
    Afdhal, Nezam
    Vierling, John M.
    Gordon, Stuart C.
    Anderson, Jane K.
    Hyland, Robert H.
    Dvory-Sobol, Hadas
    An, Di
    Hindes, Robert G.
    Albanis, Efsevia
    Symonds, William T.
    Berrey, M. Michelle
    Nelson, David R.
    Jacobson, Ira M.
    LANCET, 2013, 381 (9883): : 2100 - 2107
  • [8] Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial (vol 2, pg 319, 2015)
    Rockstroh, J. K.
    Nelson, M.
    Katlama, C.
    LANCET HIV, 2015, 2 (08): : E316 - E316
  • [9] Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial (vol 2, pg e319, 2015)
    Rockstroh, J. K.
    Nelson, M.
    Katlama, C.
    LANCET HIV, 2015, 2 (10): : E416 - E416
  • [10] Safety and efficacy of anti-pre-S1 domain monoclonal antibody (HH-003) treatment in patients with co-infection of chronic hepatitis B virus (HBV) and hepatitis D virus (HDV): a single center, open-label, phase 2 trial
    Wang, Xinrui
    Chi, Xiumei
    Zhang, Yingyu
    Gu, Yumei
    Xiao, Long
    Qi, Yonghe
    Zou, Liangfeng
    Wen, Jiaying
    Zhang, Yin
    Chen, Pan
    Lei, Cong
    Ye, Bin
    Sui, Jianhua
    Li, Wenhui
    Niu, Junqi
    JOURNAL OF HEPATOLOGY, 2023, 78 : S117 - S117
1234